Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
50 studies found for:    "Kennedy disease"
Show Display Options
RSS Create an RSS feed from your search for:
"Kennedy disease"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed
Has Results
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
Conditions: Kennedy's Disease;   Spinal and Bulbar Muscular Atrophy
Interventions: Drug: Dutasteride;   Drug: Placebo
2 Unknown  Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
Conditions: Spinobulbar Muscular Atrophy;   Kennedy's Disease
Interventions: Drug: Goserelin;   Procedure: Electrophysiologic study;   Procedure: tissue biopsy
3 Not yet recruiting High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Spinal and Bulbar Muscular Atrophy;   Healthy Subjects
Interventions: Other: Supervised high intensity training;   Other: Optional training;   Other: Control period;   Other: Unsupervised High intensity training
4 Active, not recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
5 Recruiting Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Condition: Spinal and Bulbar Muscular Atrophy
Interventions: Drug: BVS857;   Drug: Placebo
6 Completed Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
Conditions: Spinal Muscular Atrophy;   Amyotrophic Lateral Sclerosis;   Spinobulbar Muscular Atrophy
Interventions: Drug: leuprolide;   Drug: testosterone
7 Recruiting Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Intervention: Drug: AZD5312
8 Recruiting Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian;   Recurrent Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Carcinoma.
Intervention: Drug: Enzalutamide
9 Recruiting Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
Conditions: Libido;   Receptors, Androgen;   Polymorphism, Genetic;   Androgen Effect
Intervention:
10 Recruiting Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Liver;   Motor Neuron Disease
Intervention:
11 Withdrawn STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling
Condition: Adenocarcinoma of the Prostate
Interventions: Drug: STA9090;   Drug: STA9090 with Dutasteride
12 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
13 Recruiting The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: LHRH Agonist
14 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
15 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
16 Withdrawn Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery
Condition: Breast Cancer Female
Interventions: Drug: oral microencapsulated diindolylmethane;   Other: laboratory biomarker analysis
17 Recruiting A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Conditions: Pre-treated Postmenopausal Patients With ER/PgR-negative/AR-positive or ER;   and/or PgR-positive/AR-positive Metastatic Breast Cancer
Intervention: Drug: DHEA (Dehydroepiandrosterone)
18 Completed Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Drug: Finasteride
19 Recruiting A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer
Conditions: Advanced Breast Cancer;   Human Epidermal Growth Factor Receptor 2 (HER2);   HER2 Amplified
Interventions: Drug: enzalutamide;   Drug: trastuzumab
20 Recruiting A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms, Castration-Resistant
Intervention: Drug: JNJ-56021927

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years